Kieran J Rothnie

17PUBLICATIONS
29CO-AUTHORS
Clinical pharmacy and pharmacy practiceRegenerative medicine (incl. stem cells)Toxicology (incl. clinical toxicology)Environmental epidemiologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Dec 04, 2024
Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study.

Sandra Jokšaitė, Robert Wood, Afisi Ismaila

|May 21, 2024
Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.

Kieran J Rothnie, Robert P Wood, Alexandrosz Czira

|Apr 22, 2024
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.

Kai-Michael Beeh, Kieran J Rothnie, Jing Claussen

|Apr 02, 2024
Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.

Afisi S Ismaila, Kieran J Rothnie, Robert P Wood

|Dec 13, 2023
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.

Alexandrosz Czira, Shoko Akiyama, Takeo Ishii

|Nov 29, 2023
Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.

Kieran J Rothnie, Beade Numbere, Steven Gelwicks

Pageof 3

Frequent Collaborators

11 joint publications

Afisi S Ismaila

10 joint publications

Alexandrosz Czira

10 joint publications

Chris Compton

8 joint publications

Robert Wood